Fredrik Wiklund

Fredrik Wiklund joined Bright Peak in January 2020 and serves as our Chief Executive Officer, bringing over two decades of leadership and operational expertise across both emerging and established biotechnology companies. Prior to Bright Peak, Fred served as Chief Operating Officer at Bioniz Therapeutics Inc., a company developing multi-functional cytokine-based therapies for the treatment of cancer and autoimmune diseases, where he secured a ~$500 million Option and Merger agreement with Almirall S.A. Before his time at Bioniz, Fred was the Vice President of Corporate Development and later the President and CEO of Celladon Corporation (CLDN), leading the company through a successful IPO in 2014 and its merger with Eiger Pharmaceuticals in 2016. Earlier in his career, Fred was Head of Corporate Development and Investor Relations at Tercica Inc. (TRCA), overseeing the company’s IPO and its ~$650 million acquisition by Ipsen Group in 2009. He also gained valuable experience as an investment banker in the Healthcare Group at Lehman Brothers, London, and spent five years at Gilead Sciences, contributing to the launch of Gilead’s first commercial product in 1996. Fred holds a Bachelor of Arts from the University of San Diego and a Master of Business Administration from the University of Southern California.